HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PCRX
Pacira BioSciences, Inc.
PCRX's fundamentals are strong: its operating margin went from −18% to 4.8% and it turned 23% of its revenue into free cash flow. At 39x earnings, it's trading below its usual 63x. Analysts expect earnings growth, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PCRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Strong | |
| Strong |
PCRX's profitability, cash flow and balance sheet are currently healthy. There isn't enough data to rate its revenue.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PCRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 11x | $36.46 | — |
| Cheap | 19x | $17.40 | -52% |
| Current | 39x | $36.46 | — |
| Fair | 59x | $55.10 | +51% |
| Expensive | 166x | $156 | +328% |
Historical ranges are pointers, not guarantees.
PCRX's PE is in its fair range at 39x. If earnings grow as analysts expect, today's price would be 11x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PCRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect PCRX's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PCRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.23 | +244% |
| Q3 2026 | $0.94 | +92% |
| Q2 2026 | $0.36 | +$3.10 |
| Q1 2026 | $0.13 | +$2.37 |
| Q4 2025 | $0.16 | +$2.31 |
| Q3 2025 | $0.49 | +$2.44 |
| Q2 2025 | -$2.74 | -297% |
| Q1 2025 | -$2.24 | -248% |
| Q4 2024 | -$2.15 | -342% |
PCRX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PCRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PCRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $176.7M | -1.6% |
| Q2 2026 | $192.4M | +6.2% |
| Q1 2026 | $177.4M | +5% |
| Q3 2025 | $179.5M | +6.5% |
| Q2 2025 | $181.1M | +1.7% |
| Q1 2025 | $168.9M | +1.1% |
| Q3 2024 | $168.6M | +2.8% |
| Q2 2024 | $178M | +5% |
PCRX's revenue has picked up after two years of holding roughly level: $177M last quarter, down 1.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +9.1 points |
| Q2 2026 | 2.2% | -2.5 points |
| Q1 2026 | 3.9% | +2.7 points |
| Q4 2025 | 1.2% | N/A |
| Q3 2025 | 3.5% | +86 points |
| Q2 2025 | 4.7% | -11 points |
| Q1 2025 | 1.2% | -6.7 points |
| Q3 2024 | -83% | -94 points |
PCRX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PCRX on cash flow, with more consistent year-over-year improvement.
PCRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $46.4M | -18% |
| Q2 2026 | $56.1M | +503% |
| Q1 2026 | $23M | -15% |
| Q4 2025 | $43.5M | +40% |
| Q3 2025 | $57M | +14% |
| Q2 2025 | $9.3M | -82% |
| Q1 2025 | $26.9M | -42% |
| Q4 2024 | $31M | -32% |
PCRX generated $169M in free cash flow over the past year, up 36% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PCRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +530K shares |
| 1 year | -8.2% | -3.6M shares |
| 3 years | -22% | -11.2M shares |
| 5 years | -10% | -4.6M shares |
| Available history | -1.6% | -683K shares |
PCRX has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $50M |
| Q4 2025 | $48.2M |
| Q3 2025 | $50M |
| Q4 2024 | — |
| Q3 2024 | — |
PCRX spent $98M buying back its own shares over the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PCRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.9x | Healthy |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 1.7x | Healthy |
| Q4 2024 | 57.0x | High |
| Q3 2024 | -22.1x | Net Cash |
| Q2 2024 | -1.5x | Net Cash |
PCRX's net debt is less than a year of its operating earnings (EBITDA), down from 1.7 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PCRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 77.6 | Overbought |
| Stochastic | 98.3 | Overbought |
PCRX's weekly RSI is 78 (overbought) and its Stochastic is 98 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PCRX PE vs Healthcare Sector
| Metric | PCRX | Sector median | Relative |
|---|---|---|---|
| PE | 39x | 26x | 50% above |
| PE % | 37 | 29 | 8 pts above |
PCRX is trading at 39x earnings, a 50% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PCRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $33.6 | 8.5% above |
| 20 week MA | $28.6 | 27% above |
| 50 week MA | $25.4 | 44% above |
| 100 week MA | $24.7 | 48% above |
| 200 week MA | $27.3 | 33% above |
PCRX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PCRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.6 | $59.2 | +33% |
| 2021 | $59.2 | $61.7 | +4.1% |
| 2022 | $61.7 | $39.7 | -36% |
| 2023 | $39.7 | $33.7 | -15% |
| 2024 | $33.7 | $19.7 | -42% |
| 2025 | $19.7 | $26.5 | +35% |
| 2026 YTD | $26.5 | $36.5 | +38% |
PCRX has the edge over HIMS on returns for 2026, with the stronger performance.